Jardiance

Empagliflozin, the active ingredient in Jardiance, is a SGLT2 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus and is also indicated for heart failure with reduced ejection fraction and chronic kidney disease in adults.

GNH USA supplies Jardiance as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jardiance is used in several chronic conditions that involve glucose handling and cardiovascular‑renal risk.

Type 2 diabetes mellitus: improves glycaemic control by lowering blood glucose levels. Heart failure with reduced ejection fraction: reduces risk of cardiovascular death and hospitalisation. Chronic kidney disease: slows decline of renal function and reduces albuminuria.

Common Side Effects: - Genital mycotic infection: increased risk of yeast infections in both sexes. - Urinary tract infection: symptoms such as dysuria and frequency. - Increased urination: polyuria leading to mild dehydration. - Thirst: secondary to osmotic diuresis.

Serious or Rare Side Effects: - Ketoacidosis: may occur even with modest glucose elevations. - Acute kidney injury: especially in volume‑depleted patients. - Severe dehydration or hypotension: can lead to syncope. - Fournier’s gangrene: necrotising fasciitis of the perineum. - Hypersensitivity reactions: including rash, angioedema, or anaphylaxis.

Before prescribing empagliflozin, clinicians should assess individual risk factors and monitor patients regularly.

Renal function monitoring: evaluate eGFR before initiation and periodically thereafter. Volume status: ensure adequate hydration, especially in the elderly or those on diuretics. Blood pressure monitoring: watch for hypotension, particularly in patients with low baseline pressure. Genital infection counseling: advise on hygiene to reduce fungal infection risk. Contraindication in severe renal impairment: avoid use when eGFR is below the recommended threshold. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Empagliflozin may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Insulin: additive hypoglycaemia risk; dose reduction may be needed. - Loop diuretics: can exacerbate volume depletion and hypotension. - Rifampin: may lower empagliflozin plasma concentrations, reducing efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs: may impair renal function, increasing risk of AKI. - Thiazide diuretics: can increase the likelihood of dehydration and electrolyte disturbances.